News
PRGO
31.27
+0.13%
0.04
Health Care Sector Update for 04/25/2024: LAB, PRGO, BMY, AZN
NASDAQ · 3h ago
Tourlite Capital Q1 2024 Investor Letter
Tourlite Capital Management, LP is an asset management firm focused on long/short equity investing in public companies. Tourlite Fund, LP returned 6.0% for the First Quarter of 2024. The Fund has annualized returns of 10.0%, compared to the S&P 500 and Russell 2000.
Seeking Alpha · 8h ago
Perrigo gets offer to sell its HRA Pharma rare diseases unit
Perrigo gets offer to sell its HRA Pharma rare diseases unit to Esteve Healthcare for a total consideration of up to €275 million. The firm expects to use the net proceeds for debt repayment. The proposed deal is expected to close in the third quarter of 2024.
Seeking Alpha · 12h ago
BRIEF-Perrigo Receives Binding Offer To Divest Its HRA Pharma Rare Diseases Business For Up To €275 Mln
Perrigo Receives Binding Offer To Divest Its HRA Pharma Rare Diseases Business For Up To €275 Mln. Perrigo receives offer to sell business for up to €275 million. The company expects to use the money to pay off debt and invest in new products.
Reuters · 12h ago
Perrigo Secures Binding Offer To Divest Its HRA Pharma Rare Diseases Business For Up To €275M
The total consideration of up to €275 million is expected to include an upfront cash payment of €190 million. The Rare Diseases business is to be sold to Perrigo in a deal expected to close in the third quarter of 2024. The deal includes potential earnout payments based on sales milestones.
Benzinga · 13h ago
PERRIGO COMPANY PLC - TOTAL CONSIDERATION WOULD BE ACCRETIVE TO PERRIGO'S CURRENT ENTERPRISE VALUE-TO-EBITDA MULTIPLE
Reuters · 13h ago
Perrigo Receives Binding Offer to Divest its HRA Pharma Rare Diseases Business for up to €275 Million
Proposed Divestment of Branded Prescription Pharma Business Further Supports Perrigo's Strategic Focus on Consumer Self-Care. Total Purchase Consideration of up to €275 million, consisting of €190 million in Cash Upfront and €85 million in Potential Earnouts. The proposed transaction is expected to close in the third quarter of 2024. Esteve Healthcare, S.L. Has signed a binding offer to acquire Perriga's HRA Pharma Rare Diseases business.
PR Newswire · 13h ago
99% Of This Perrigo Insider's Holdings Were Sold
Perrigo Company plc's (NYSE:PRGO) insiders sold shares in the last year. The biggest insider sale was by Murray Kessler for US$7.1m worth of shares at US$35.75 per share. In the last quarter, Perrigo insiders bought US$526k of shares. The company owns 0.5% of Perriga. But the company has sold more shares than it bought in the past 12 months. It's a good sign to see an insider sale of shares in a company.
Simply Wall St · 1d ago
Gerber, Perrigo sued over 'store-brand' infant formula prices
Gerber, Perrigo sued over 'store-brand' infant formula prices. The lawsuit says the formula makers illegally agreed to block competitors from cutting into the market for store-brand formula. The plaintiffs are four consumers of formula sold at Walmart, Walgreens and other retailers.
Reuters · 2d ago
Perrigo to Release First Quarter 2024 Financial Results on May 7, 2024
Perrigo Company plc plans to issue its first quarter 2024 financial results on Tuesday, May 7th, 2024. The earnings conference call will be available live via webcast. Perrigo is a leading provider of Consumer Self-Care Products and over-the-counter health and wellness solutions.
PR Newswire · 2d ago
Weekly Report: what happened at PRGO last week (0415-0419)?
Weekly Report · 3d ago
Heartland Mid Cap Value Fund Q1 2024 Portfolio Manager Commentary
Seeking Alpha · 04/17 14:55
Weekly Report: what happened at PRGO last week (0408-0412)?
Weekly Report · 04/15 09:15
Perrigo Price Target Maintained With a $42.00/Share by Canaccord Genuity
Dow Jones · 04/12 16:01
Perrigo Is Maintained at Buy by Canaccord Genuity
Dow Jones · 04/12 16:01
Canaccord Genuity Maintains Buy on Perrigo, Maintains $42 Price Target
Benzinga · 04/12 15:50
Perrigo Co Plc: Statement of changes in beneficial ownership of securities
Press release · 04/09 22:49
Opill and WNBA Team Up for Groundbreaking Partnership
Opill® is the first-ever daily birth control pill available without a prescription in the U.S. Opill will be an Associate Partner of the 2024 WNBA Draft. The WNBA is committed to building confidence, strength and health equity. The two brands will collaborate on a program to reach students on college campuses.
PR Newswire · 04/09 16:30
Upcoming Catalysts Position Perrigo For Sustained Long-Term Dividend Growth
Perrigo is a leading provider of over-the-counter medications and therapeutic products. The company has increased its dividends for 20 consecutive years. Infant formula woes will be resolved in 2024 and the company is poised to turn the corner. Perrigo has five potential catalysts in 2024 that could support a share price increase.
Seeking Alpha · 04/09 09:49
Disney To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Monday
Canaccord Genuity boosted the price target for CervoMed Inc. The Walt Disney Company shares rose 1.1% to close at $118.38 on Friday. Susquehanna increased the price targets for Transocean Ltd. And Sealed Air Corporation.
Benzinga · 04/08 12:00
More
Webull provides a variety of real-time PRGO stock news. You can receive the latest news about Perrigo Co Plc through multiple platforms. This information may help you make smarter investment decisions.
About PRGO
Perrigo Company plc is an Ireland-based provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. The Company's segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises its consumer self-care business (OTC, infant formula, and oral care categories, and contract manufacturing) in the United States and Canada, including the HRA Pharma self-care business (Women's Health and Skin-Care categories) in the United States and Canada. The CSCI segment comprises its consumer self-care business in Europe and Australia, which are primarily branded, its store brand business in the United Kingdom and parts of Europe and Asia and includes the HRA Pharma self-care business (Women's Health, Skin-Care and Rare-Disease categories) in Europe. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, Nutrition and others.